GXR RM (Glucophage® Extended Release Reduced Mass) 500 Milligram (mg) Korea Bioequivalence (BE) Study

NCT ID: NCT04684420

Last Updated: 2023-12-29

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 81 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-12-22
• Study Completion Date: 2022-03-11

Brief Summary

The purpose of this study was to assess bioequivalence (BE) of newly developed Glucophage® XR (GXR) reduced mass (RM) tablet (metformin hydrochloride 500 milligrams (mg) test tablet) and marketed Glucophage ® XR tablet (metformin hydrochloride 500 mg reference tablet) following single oral dose administration under fasted and fed conditions by comparing pharmacokinetics, safety and tolerability between test and reference in healthy participants.

Conditions

Healthy

Keywords

Diabetes Mellitus; Glucophage Extended Release; Bioequivalence Study

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

First Reference GXR (Fasting), Then Test GXR RM (Fasting)

Participants received a single oral dose of 500 milligram (mg) of reference GXR (Glucophage® Extended Release) tablet on Day 1 in treatment period 1 followed by single oral dose of 500 mg test GXR RM (Reduced Mass) tablet on Day 8 in treatment period 2 under fasting conditions. There was a washout period of 7 days between two treatment period.

Group Type: EXPERIMENTAL

Glucophage® XR RM Test

Intervention Type: DRUG

Participants received a single oral dose of 500 mg of test Glucophage® XR RM tablet under fasting or fed conditions.

Glucophage® XR Reference

Intervention Type: DRUG

Participants received a single oral dose of 500 mg of reference Glucophage® XR tablet under fasting or fed conditions.

First Test GXR RM (Fasting), Then Reference GXR (Fasting)

Participants received a single oral dose of 500 milligrams (mg) of test GXR RM tablet on Day 1 in treatment period 1 followed by single oral dose of 500 mg of reference GXR tablet on Day 8 in treatment period 2 under fasting conditions. There was a washout period of 7 days between two treatment period.

Group Type: EXPERIMENTAL

Glucophage® XR RM Test

Intervention Type: DRUG

Participants received a single oral dose of 500 mg of test Glucophage® XR RM tablet under fasting or fed conditions.

Glucophage® XR Reference

Intervention Type: DRUG

Participants received a single oral dose of 500 mg of reference Glucophage® XR tablet under fasting or fed conditions.

First Reference GXR (Fed), Then Test GXR RM (Fed)

Participants received a single oral dose of 500 milligrams (mg) of reference GXR tablet on Day 1 in treatment period 1 followed by single oral dose of 500 mg of test GXR RM tablet on Day 8 in treatment period 2 under fed conditions. There was a washout period of 7 days between two treatment period.

Group Type: EXPERIMENTAL

Glucophage® XR RM Test

Intervention Type: DRUG

Participants received a single oral dose of 500 mg of test Glucophage® XR RM tablet under fasting or fed conditions.

Glucophage® XR Reference

Intervention Type: DRUG

Participants received a single oral dose of 500 mg of reference Glucophage® XR tablet under fasting or fed conditions.

First Test GXR RM (Fed), Then Reference GXR (Fed)

Participants received a single oral dose of 500 milligrams (mg) of test GXR RM tablet on Day 1 in treatment period 1 followed by single oral dose of 500 mg of reference GXR tablet on Day 8 in treatment period 2 under fed conditions. There was a washout period of 7 days between two treatment period.

Group Type: EXPERIMENTAL

Glucophage® XR RM Test

Intervention Type: DRUG

Participants received a single oral dose of 500 mg of test Glucophage® XR RM tablet under fasting or fed conditions.

Glucophage® XR Reference

Intervention Type: DRUG

Participants received a single oral dose of 500 mg of reference Glucophage® XR tablet under fasting or fed conditions.

Interventions

Glucophage® XR RM Test

Participants received a single oral dose of 500 mg of test Glucophage® XR RM tablet under fasting or fed conditions.

Intervention Type: DRUG

Glucophage® XR Reference

Participants received a single oral dose of 500 mg of reference Glucophage® XR tablet under fasting or fed conditions.

Intervention Type: DRUG

Other Intervention Names

Metformin hydrochloride; Metformin hydrochloride

Eligibility Criteria

Inclusion Criteria

• All values for hematology and biochemistry tests of blood and urinalysis (especially Estimated Glomerular Filtration Rate [eGFR] greater than [>] 80 milliliters per minute per 1.73 square meter [80 ml/min/1.73 m^2] and normal Creatinine) within the normal range or showing no clinically relevant deviation as judged by the Investigator
• Are not having congenital or chronic diseases, nor pathological symptoms based on the screening
• Have no history of gastrointestinal resection that may affect drug absorption
• Have no history of psychiatric disorder within 5 years prior to screening
• Vital signs (body temperature [tympanic], blood pressure [BP], and pulse rate in sitting position) within the normal range or showing no clinically relevant deviation as judged by the Investigator
• Electrocardiogram recording (12-lead) without signs of clinically relevant pathology in particular QTc (Bazett) less than or equal to [<=] 450 millisecond (ms)
• Non-smoker (that is [i.e.] zero cigarettes, pipes, cigars or others) at least three months before study entry
• Negative screen for Hepatitis B surface antigen (HBsAg) and Hepatitis B Virus antibody (anti-HBc), Hepatitis C Virus antibody (anti-HCV) and Human Immunodeficiency Virus antibodies (anti-HIV 1 and 2) and Rapid Plasma Reagin Antibody (RPR Ab)
• Have a body weight within the range 55 to 95 kilograms (kg) and a Body Mass Index (BMI) within the range 18.5 to 29.9 kilograms per square meter (kg/m^2) (inclusive)

Exclusion Criteria

• Participants determined ineligible to participate in this study at the discretion of the Principal Investigator (or delegated investigators)
• Hypersensitivity to venous puncture
• Known hypersensitivity to ingredients of Study Interventions or Biguanides, or having other clinically relevant hypersensitivities
• Type I diabetes mellitus, lactic acidosis, acute or chronic metabolic acidosis including diabetic ketoacidosis, with or without coma; diabetic pre-coma, pre-diabetes
• Participants with renal impairment (eGFR < 80 ml/min/1.73m^2) - calculations according to Modification of Diet in Renal Disease (MDRD) formula). Participants presenting with acute conditions with the potential to alter renal function such as dehydration, severe infection, cardiovascular collapse (shock), acute myocardial infraction, and septicemia
• Participants with acute and unstable heart failure
• Participants with severe infection or severe traumatic general disorder
• Participants who are scheduled to undergo surgical procedures
• Participants with malnutrition, inanition, pituitary dysfunction or adrenal function failure
• Participants with hepatic dysfunction, acute or chronic disease which may cause tissue hypoxia such as respiratory failure, acute myocardial infarction, shock and gastrointestinal (GI) disorder such as excessive alcohol intake, hydration, diarrhea, vomiting etc.
• Participants undergoing intravascular administration of iodinated contrast materials in radio diagnostic examinations (for example, intravenous urogram, intravenous cholangiography, angiography, and computed tomography (CT) scans with intravascular contrast materials etc.)
• Participants who took drugs that significantly induce (e.g., barbiturate) or inhibit drug metabolism enzymes, and those drugs that may alter metformin pharmacokinetic (pK), most importantly organic cation transporter 1/2 [OCT1/2] inhibitors and inducers, within 30 days prior to screening
• Use of a concomitant drug. However, any medications that are considered necessary for participant's welfare and will not interfere with the trial medication may be given at the discretion of the investigator
• Use of any medication that may affect the outcome of the study within 10 days prior to screening and during study conduct
• Participation in another bioequivalence or other clinical studies where the last administration of previous study medication was within 6 months, before the first drug administration in this study

• Minimum Eligible Age: 19 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Medical Responsible

Role: STUDY_DIRECTOR

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Locations

Clinical Trials Center, Chungnam National University Hospital

Daejeon, , South Korea

Countries

South Korea

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Related Links

https://clinicaltrials.emdgroup.com/en/trial-details/?id=MS200084_0028

Trial Awareness and Transparency website

https://www.merckgroup.com/en/company/contact-us/medinfo-contact-map.html

Medical Information Location Map - Med Info Contact

Other Identifiers

MS200084_0028

Identifier Type: -

Identifier Source: org_study_id